Dr. Chengcheng Guo 郭琤琤
Chief Physician
Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment for brain tumors, including chemotherapy, immunotherapy, and targeted therapy. Conditions include brain metastases, glioma, germ cell tumors, medulloblastoma, lymphoma, and rare central nervous system malignancies.
Dr. Guo has nearly 20 years of clinical oncology experience. After earning a PhD in tumor chemotherapy from Sun Yat-sen University in 2012, Dr. Guo completed postdoctoral research at MD Anderson Cancer Center (2010–2012), studying CNS tumor treatments and tumor marker mechanisms. Dr. Guo leads multiple research projects and participates in international glioma clinical trials.
Professional roles
- Standing Committee Member, Youth Committee of South China Clinical Oncology Collaboration Group
- Member, Neuro-Oncology Professional Committee, China Anti-Cancer Association
- Reviewer, Molecular Medicine Reports
- Reviewer, Glioma
Name order: in Chinese the family name comes first (Guo Chengcheng). Papers usually list the name as Chengcheng Guo or Guo C.
Selected publications
67 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- Discov Oncol, 2025 (first author): VAL-083 is effective in patients with newly-diagnosed MGMT-unmethylated glioblastoma: report of phase II study. PubMed 41385182
- Curr Neurol Neurosci Rep, 2025 (senior author): Ependymoma: Advances in Systems Treatment Strategies. PubMed 41123729
- Discov Oncol, 2025 (senior author): Voxel-wise analysis of brain metastasis predilection sites in breast cancer by clinical features. PubMed 41026369
- Front Immunol, 2025 (senior author): Development and validation of a nomogram for predicting overall survival in patients with primary central nervous system germ cell tumors. PubMed 40909273
- Chemotherapy, 2025 (first author): Phase I Clinical Study of a Multi-Kinase Inhibitor TG02 Capsule for the Treatment of Recurrent High-Grade Gliomas with Failed Temozolomide Treatment in Chinese Patients. PubMed 39557019
- Clin Neurol Neurosurg, 2024 (senior author): A novel lactate dehydrogenase-based risk score model to predict the prognosis of primary central nervous system germ cell tumor treated with chemoradiotherapy. PubMed 38091701
- JAMA Netw Open, 2023 (first author): Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial. PubMed 36705923
- Cancer Cell Int, 2022 (senior author): Prognostic value of the modified systemic inflammation score in non-small-cell lung cancer with brain metastasis. PubMed 36242047
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion